JP2007519692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519692A5 JP2007519692A5 JP2006550294A JP2006550294A JP2007519692A5 JP 2007519692 A5 JP2007519692 A5 JP 2007519692A5 JP 2006550294 A JP2006550294 A JP 2006550294A JP 2006550294 A JP2006550294 A JP 2006550294A JP 2007519692 A5 JP2007519692 A5 JP 2007519692A5
- Authority
- JP
- Japan
- Prior art keywords
- indazol
- fluoro
- methyl
- substituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- -1 —CONHR 13 Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- NDSAZMGBKQEREV-UHFFFAOYSA-N 3-fluoro-5-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methyl-n-(2-methylpyrazol-3-yl)benzamide Chemical compound CC1=C(F)C=C(C(=O)NC=2N(N=CC=2)C)C=C1C(C=C1NN=2)=CC=C1C=2C1=CC=C(F)C=C1 NDSAZMGBKQEREV-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- FFLVSPSGKSYFOD-UHFFFAOYSA-N N-cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzoxazol-6-yl]-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(C=C1ON=2)=CC=C1C=2C1=CC=C(O)C=C1 FFLVSPSGKSYFOD-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 229910052731 fluorine Chemical group 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 150000002429 hydrazines Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XXKHSBRGJGQQJN-UHFFFAOYSA-N n-(2,4-dimethylpyrazol-3-yl)-3-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound C1=NN(C)C(NC(=O)C=2C=C(C(C)=CC=2)C=2C=C3NN=C(C3=CC=2)C=2C=CC(F)=CC=2)=C1C XXKHSBRGJGQQJN-UHFFFAOYSA-N 0.000 claims 1
- QXTNFKQMOZXGAJ-UHFFFAOYSA-N n-(2,4-dimethylpyrazol-3-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound C1=NN(C)C(NC(=O)C=2C=C(C(C)=C(F)C=2)C=2C=C3NN=C(C3=CC=2)C=2C=CC(F)=CC=2)=C1C QXTNFKQMOZXGAJ-UHFFFAOYSA-N 0.000 claims 1
- IAHWGNBUSRCASO-UHFFFAOYSA-N n-(2-ethylpyrazol-3-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound CCN1N=CC=C1NC(=O)C1=CC(F)=C(C)C(C=2C=C3NN=C(C3=CC=2)C=2C=CC(F)=CC=2)=C1 IAHWGNBUSRCASO-UHFFFAOYSA-N 0.000 claims 1
- UVOQFNITQPYYOI-UHFFFAOYSA-N n-cyclopropyl-3-[1-[4-(2,3-dihydroxypropylamino)phenyl]indazol-5-yl]-5-fluoro-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(C=C1C=N2)=CC=C1N2C1=CC=C(NCC(O)CO)C=C1 UVOQFNITQPYYOI-UHFFFAOYSA-N 0.000 claims 1
- JWLBNZMPMCOTIL-UHFFFAOYSA-N n-cyclopropyl-3-[1-[4-[2-(dimethylamino)ethylamino]phenyl]indazol-5-yl]-5-fluoro-4-methylbenzamide Chemical compound C1=CC(NCCN(C)C)=CC=C1N1C2=CC=C(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=C2C=N1 JWLBNZMPMCOTIL-UHFFFAOYSA-N 0.000 claims 1
- BGMAADGYDIEDFZ-UHFFFAOYSA-N n-cyclopropyl-3-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1NN=2)=CC=C1C=2C1=CC=C(F)C=C1 BGMAADGYDIEDFZ-UHFFFAOYSA-N 0.000 claims 1
- GQBCGYCOKDKXLT-UHFFFAOYSA-N n-cyclopropyl-3-[3-(4-methoxyphenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1C1=NNC2=CC(C=3C(=CC=C(C=3)C(=O)NC3CC3)C)=CC=C12 GQBCGYCOKDKXLT-UHFFFAOYSA-N 0.000 claims 1
- YDTSBAIFSIHQBL-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-(1-phenylindazol-5-yl)benzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(C=C1C=N2)=CC=C1N2C1=CC=CC=C1 YDTSBAIFSIHQBL-UHFFFAOYSA-N 0.000 claims 1
- XAFMUBMMTNHFMW-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[1-(4-methylsulfonylphenyl)indazol-5-yl]benzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(C=C1C=N2)=CC=C1N2C1=CC=C(S(C)(=O)=O)C=C1 XAFMUBMMTNHFMW-UHFFFAOYSA-N 0.000 claims 1
- CYKMFIZQLQHACP-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[2-(methylamino)-2-oxoethyl]phenyl]indazol-5-yl]benzamide Chemical compound C1=CC(CC(=O)NC)=CC=C1N1C2=CC=C(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=C2C=N1 CYKMFIZQLQHACP-UHFFFAOYSA-N 0.000 claims 1
- GEURZXJNLFHMMI-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)indazol-5-yl]-4-methylbenzamide Chemical compound CC1=CC(F)=CC=C1N1C2=CC=C(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=C2C=N1 GEURZXJNLFHMMI-UHFFFAOYSA-N 0.000 claims 1
- OYTNAQPOJGJNTO-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)indazol-5-yl]-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(C=C1C=N2)=CC=C1N2C1=CC=C(F)C=C1 OYTNAQPOJGJNTO-UHFFFAOYSA-N 0.000 claims 1
- LCZCYDAXLUAHIR-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[3-(4-methoxyphenyl)-1,2-benzoxazol-6-yl]-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1C1=NOC2=CC(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)=CC=C12 LCZCYDAXLUAHIR-UHFFFAOYSA-N 0.000 claims 1
- DVFVWYWKPJGSHJ-UHFFFAOYSA-N n-ethyl-3-[3-(4-fluorophenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound CCNC(=O)C1=CC=C(C)C(C=2C=C3NN=C(C3=CC=2)C=2C=CC(F)=CC=2)=C1 DVFVWYWKPJGSHJ-UHFFFAOYSA-N 0.000 claims 1
- QXXQWHJTTDKUMU-UHFFFAOYSA-N n-ethyl-3-[3-(4-methoxyphenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound CCNC(=O)C1=CC=C(C)C(C=2C=C3NN=C(C3=CC=2)C=2C=CC(OC)=CC=2)=C1 QXXQWHJTTDKUMU-UHFFFAOYSA-N 0.000 claims 1
- ICUDUXKKHGONMS-UHFFFAOYSA-N n-ethyl-3-fluoro-5-[3-(4-fluoro-2-methoxyphenyl)-1h-indazol-6-yl]-4-methylbenzamide Chemical compound CCNC(=O)C1=CC(F)=C(C)C(C=2C=C3NN=C(C3=CC=2)C=2C(=CC(F)=CC=2)OC)=C1 ICUDUXKKHGONMS-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402143.2A GB0402143D0 (en) | 2004-01-30 | 2004-01-30 | Novel compounds |
| PCT/GB2005/000265 WO2005073189A1 (en) | 2004-01-30 | 2005-01-27 | Fused heteroyral derivatives for use as p38 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519692A JP2007519692A (ja) | 2007-07-19 |
| JP2007519692A5 true JP2007519692A5 (2) | 2008-03-13 |
Family
ID=31971803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550294A Pending JP2007519692A (ja) | 2004-01-30 | 2005-01-27 | ｐ３８キナーゼ阻害剤として使用するための縮合ヘテロアリール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090023725A1 (2) |
| EP (1) | EP1708996B1 (2) |
| JP (1) | JP2007519692A (2) |
| AT (1) | ATE406351T1 (2) |
| DE (1) | DE602005009318D1 (2) |
| ES (1) | ES2313283T3 (2) |
| GB (1) | GB0402143D0 (2) |
| WO (1) | WO2005073189A1 (2) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) * | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| GB0402140D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| WO2008001929A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Treatment agent for inflammatory bowel disease |
| WO2008055842A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| AU2008215659B2 (en) | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| WO2008136948A1 (en) * | 2007-05-07 | 2008-11-13 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use |
| WO2008137176A1 (en) * | 2007-05-07 | 2008-11-13 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| CA2710039C (en) | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| US8367671B2 (en) | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| MY148558A (en) | 2008-09-11 | 2013-04-30 | Amgen Inc | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| WO2010071583A1 (en) * | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
| WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| EP2504330A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
| EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| MX2012013197A (es) | 2010-05-12 | 2013-04-03 | Abbvie Inc | Inhibidores de indazol de cinasa. |
| US8921363B2 (en) | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
| US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
| US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
| EP2675810A1 (en) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| WO2021038419A1 (en) * | 2019-08-23 | 2021-03-04 | Insilico Medicine Ip Limited | Kinase inhibitors and methods of synthesis and treatment |
| US12293809B2 (en) | 2019-08-23 | 2025-05-06 | Insilico Medicine Ip Limited | Workflow for generating compounds with biological activity against a specific biological target |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) * | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| MX16687A (es) * | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
| GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| IL108630A0 (en) * | 1993-02-18 | 1994-05-30 | Fmc Corp | Insecticidal substituted 2,4-diaminoquinazolines |
| GB9408577D0 (en) * | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
| US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| EP0849256B1 (en) * | 1995-08-22 | 2005-06-08 | Japan Tobacco Inc. | Amide compounds and use of the same |
| US6323227B1 (en) * | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| PL187516B1 (pl) * | 1996-01-11 | 2004-07-30 | Smithkline Beecham Corp | Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki |
| FR2754260B1 (fr) * | 1996-10-04 | 1998-10-30 | Adir | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| IL132736A0 (en) * | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| AU7966198A (en) * | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| US6251914B1 (en) * | 1997-07-02 | 2001-06-26 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| DK1032575T3 (da) * | 1997-09-05 | 2003-10-20 | Glaxo Group Ltd | 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor |
| US6376546B1 (en) * | 1997-10-14 | 2002-04-23 | Asahi Kasei Kabushiki Kaisha | Biphenyl-5-alkanoic acid derivatives and use thereof |
| DE19817461A1 (de) * | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Benzamide, deren Herstellung und Anwendung |
| PL195600B1 (pl) * | 1998-05-15 | 2007-10-31 | Astrazeneca Ab | Pochodne benzamidowe, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie do wytwarzania leku do leczenia stanów medycznych powstających za pośrednictwem cytokin |
| US6867209B1 (en) * | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
| US6130235A (en) * | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6448257B1 (en) * | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP2002526482A (ja) * | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000047553A2 (en) * | 1999-02-11 | 2000-08-17 | Cor Therapeutics Inc. | ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa |
| ATE261444T1 (de) * | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| US6509361B1 (en) * | 1999-05-12 | 2003-01-21 | Pharmacia Corporation | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors |
| CA2374947A1 (en) * | 1999-05-24 | 2000-11-30 | Robert M. Scarborough | Inhibitors of factor xa |
| DE19932571A1 (de) * | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| US6576632B1 (en) * | 1999-08-27 | 2003-06-10 | Pfizer Inc | Biaryl compounds useful as anticancer agents |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10060807A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| WO2002055517A2 (en) * | 2000-12-20 | 2002-07-18 | Jingrong Cui | 4-(hetero)aryl substituted indolinones |
| DE10110749A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| HUP0303415A2 (hu) * | 2001-03-09 | 2004-01-28 | Pfizer Products Inc. | Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények |
| ATE438615T1 (de) * | 2001-04-06 | 2009-08-15 | Biocryst Pharm Inc | Biarylverbindungen als serinproteaseinhibitoren |
| FR2824827B1 (fr) * | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) * | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| GB0209891D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| US20040116479A1 (en) * | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| US7136850B2 (en) * | 2002-12-20 | 2006-11-14 | International Business Machines Corporation | Self tuning database retrieval optimization using regression functions |
| US7396943B2 (en) * | 2003-03-07 | 2008-07-08 | Eli Lilly And Company | Opioid receptor antagonists |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| EP1687284B1 (en) * | 2003-07-25 | 2008-10-29 | Novartis AG | p-38 KINASE INHIBITORS |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
-
2004
- 2004-01-30 GB GBGB0402143.2A patent/GB0402143D0/en not_active Ceased
-
2005
- 2005-01-27 AT AT05702022T patent/ATE406351T1/de not_active IP Right Cessation
- 2005-01-27 ES ES05702022T patent/ES2313283T3/es not_active Expired - Lifetime
- 2005-01-27 US US10/587,790 patent/US20090023725A1/en not_active Abandoned
- 2005-01-27 DE DE602005009318T patent/DE602005009318D1/de not_active Expired - Lifetime
- 2005-01-27 WO PCT/GB2005/000265 patent/WO2005073189A1/en not_active Ceased
- 2005-01-27 JP JP2006550294A patent/JP2007519692A/ja active Pending
- 2005-01-27 EP EP05702022A patent/EP1708996B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007519692A5 (2) | ||
| JP2007519695A5 (2) | ||
| JP2024521920A5 (2) | ||
| JP4485354B2 (ja) | 新規な置換インドール類 | |
| EP1242396B1 (en) | New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| JP2008517945A5 (2) | ||
| JP4669836B2 (ja) | ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途 | |
| JP2005535586A5 (2) | ||
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| US7595323B2 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2010513283A5 (2) | ||
| WO2002010146A1 (en) | Carboxamide compounds and their use as antagonists of a human 11cby receptor | |
| JP2008500991A (ja) | 医学的使用のためのｃｒｔｈ２レセプターリガンド | |
| MXPA04011209A (es) | Derivados de piridazin-3(2h)-ona como inhibidores de pde4. | |
| JP2007509130A5 (2) | ||
| JP2011526594A5 (2) | ||
| SK627790A3 (en) | Derivative of 2-aminothiazole or 2-aminooxazole and 5-amino- -1,2,4-oxadiazole or 5-amino-1,2,4-oxathiazole, a process for preparation thereof and pharmaceutical composition containing the same | |
| CA2340952A1 (en) | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists | |
| SK35393A3 (en) | 1,2,4- oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | |
| JP2008513464A5 (2) | ||
| TW201011019A (en) | Polysubstituted azetidine compounds, their preparation and their therapeutic application | |
| CN101472921B (zh) | 吡啶基异*唑衍生物 | |
| JPS6117562A (ja) | 薬剤に有用なジヒドロピリジニルジカルボン酸アミド及びエステル | |
| CA2529126A1 (en) | Azetidine compounds |